Synthetic Biologics Inc. (NYSE:SYN) has a beta value of 1.85 and has seen 2,161,681 shares traded in the last trading session. The company, currently valued at $74.29 Million, closed the last trade at $0.57 per share which meant it lost -$0.01 on the day or -2.05% during that session. The SYN stock price is -198.25% off its 52-week high price of $1.7 and 56.14% above the 52-week low of $0.25. If we look at the company’s 10-day average daily trading volume, we find that it stood at 4.95 Million shares traded. The 3-month trading volume is 17.68 Million shares.
The consensus among analysts is that Synthetic Biologics Inc. (SYN) is a Buy stock at the moment, with a recommendation rating of 2. None of the analysts rate the stock as a Sell, while none rate it as Overweight. None out of 2 have rated it as a Hold, with 2 advising it as a Buy. None have rated the stock as Underweight. The expected earnings per share for the stock is -$0.02.
Synthetic Biologics Inc. (NYSE:SYN) trade information
Despite being -2.05% in the red in last session, the stock has traded in the green over the last five days, with the highest price hit on Wednesday, Apr 28 when the SYN stock price touched $0.6247 or saw a rise of 8.28%. Year-to-date, Synthetic Biologics Inc. shares have moved 49.61%, while the 5-day performance has seen it change 5.86%. Over the past 30 days, the shares of Synthetic Biologics Inc. (NYSE:SYN) have changed -15.01%. Short interest in the company has seen 5.62 Million shares shorted with days to cover at 0.32.
Wall Street analysts have a consensus price target for the stock at $1.88, which means that the shares’ value could jump 229.82% from current levels. The projected low price target is $1.25 while the price target rests at a high of $2.5. In that case, then, we find that the current price level is +338.6% off the targeted high while a plunge would see the stock lose 119.3% from current levels.
Synthetic Biologics Inc. (SYN) estimates and forecasts
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was +48.9% over the past 5 years. Earnings growth for 2021 is a modest +32.5%.
Synthetic Biologics Inc. (NYSE:SYN)’s Major holders
Insiders own 1.77% of the company shares, while shares held by institutions stand at 1.53% with a share float percentage of 1.56%. Investors are also buoyed by the number of investors in a company, with Synthetic Biologics Inc. having a total of 30 institutions that hold shares in the company. The top two institutional holders are Renaissance Technologies, LLC with over 1.24 Million shares worth more than $474.05 Thousand. As of December 30, 2020, Renaissance Technologies, LLC held 0.95% of shares outstanding.
The other major institutional holder is Fisher Asset Management, LLC, with the holding of over 127.7 Thousand shares as of March 30, 2021. The firm’s total holdings are worth over $87.12 Thousand and represent 0.1% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are Bridgeway Funds Inc-Ultra Small Company Market Fund and Valic Company I-Small Cap Fd. As of December 30, 2020, the former fund manager holds about 0.06% shares in the company for having 74300 shares of worth $28.46 Thousand while later fund manager owns 35Thousand shares of worth $23.57 Thousand as of February 27, 2021, which makes it owner of about 0.03% of company’s outstanding stock.